Fennec Pharmaceuticals (FENC) Cost of Revenue (2023 - 2026)
Fennec Pharmaceuticals' (FENC) quarterly Cost of Revenue came in at $1.8 million in Q4 2025, up 163.68% YoY from $669000.0 in Q4 2024, and up 167.27% on a QoQ basis from $660000.0 in Q3 2025.
Fennec Pharmaceuticals (FENC) Cost of Revenue (2023 - 2026) Analysis & Trends
Fennec Pharmaceuticals (FENC) has 3 years of Cost of Revenue data on file, last reported at $1.8 million in Q4 2025.
- Quarterly Cost of Revenue rose 163.68% year-over-year to $1.8 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $3.8 million (up 18.22% YoY) and the FY2025 annual result came in at $3.8 million, up 18.22% from the prior year.
- Cost of Revenue rose to $1.8 million in Q4 2025, from $660000.0 in the prior quarter.
- In the past five years, Cost of Revenue ranged from a high of $1.8 million in Q4 2025 to a low of $95000.0 in Q1 2023.
- A 3-year average of $683916.7 and a median of $634000.0 in 2024 frame the typical range for Cost of Revenue.
- Annual changes were most pronounced in 2024 — Cost of Revenue surged 478.95% — and 2025, when it slumped 51.36%.
- Tracing FENC's Cost of Revenue over 3 years: stood at $685000.0 in 2023, then fell by 2.34% to $669000.0 in 2024, then surged by 163.68% to $1.8 million in 2025.
- The last three Cost of Revenue figures came in at $1.8 million (Q4 2025), $660000.0 (Q3 2025), and $967000.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 489.20 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 360.70 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 145.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 174.53 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 1.18 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 298.26 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 67.21 Mn |
| 10 | Fennec Pharmaceuticals | 410.60 Mn | 369.35 Mn | 17.15 Mn | 721,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 721,000.00 |
| Jun 30, 2026 | 721,000.00 |
| Dec 31, 2025 | 1.76 Mn |
| Dec 31, 2025 | 1.76 Mn |
| Sep 30, 2025 | 660,000.00 |
| Sep 30, 2025 | 660,000.00 |
| Jun 30, 2025 | 967,000.00 |
| Jun 30, 2025 | 967,000.00 |
| Mar 31, 2025 | 373,000.00 |
| Mar 31, 2025 | 373,000.00 |
| Dec 31, 2024 | 669,000.00 |
| Dec 31, 2024 | 669,000.00 |
| Sep 30, 2024 | 1.36 Mn |
| Sep 30, 2024 | 1.36 Mn |
| Jun 30, 2024 | 608,000.00 |
| Jun 30, 2024 | 608,000.00 |
| Mar 31, 2024 | 550,000.00 |
| Mar 31, 2024 | 550,000.00 |
| Dec 31, 2023 | 685,000.00 |
| Dec 31, 2023 | 685,000.00 |